Intranasal corticosteroids for mild childhood obstructive sleep apnea--a randomized, placebo-controlled study.

BACKGROUND

The use of non-surgical treatment for childhood obstructive sleep apnea (OSA) is gaining popularity, especially in children with mild disease.

OBJECTIVE

To test the hypothesis that intranasal corticosteroids reduce disease severity in children with mild OSA.

STUDY

DESIGN

A randomized, double-blinded, placebo-controlled trial of intranasal mometasone furoate (MF) versus placebo in children aged 6 to 18 years with mild OSA. The primary outcome was the change from baseline obstructive apnea hypopnea index (OAHI), as documented by overnight polysomnography, after four months of treatment.

RESULTS

Sixty-two children were recruited but 12 dropped out. This left 24 and 26 children for final analysis in the MF and placebo group, respectively. The OAHI and oxygen desaturation index (ODI) improved significantly in the MF group only. The OAHI decreased from 2.7 ± 0.2 to 1.7 ± 0.3 in the MF group, but increased from 2.5 ± 0.2 to 2.9 ± 0.6 in the placebo group (p = 0.039). The mean changes in ODI in the MF group and placebo group were -0.6 ± 0.5 and +0.7 ± 0.4, respectively (p = 0.037).

CONCLUSION

Four months of treatment with intranasal mometasone furoate effectively reduces the severity of mild OSA in children.